Detalhe da pesquisa
1.
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
Cancer Immunol Immunother
; 62(12): 1841-9, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24162108
2.
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Blood
; 118(24): 6387-91, 2011 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22031859